Risk of infections in psoriasis: assessment and challenges in daily management

References

• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983–994.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
   PubMed Web of Science ®Google Scholar
• Christophers E. Psoriasis–epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314–320.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, et al. risk factors for the development of psoriasis. Int J Mol Sci. 2019;20:4347.
   PubMed Web of Science ®Google Scholar
• Dopytalska K, Sobolewski P, Blaszczak A, et al. Psoriasis in special localizations. Reumatologia. 2018;56:392–398.
   PubMedGoogle Scholar
• Ayala-Fontanez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.
   PubMedGoogle Scholar
• Baylet A, Laclaverie M, Marchand L, et al. Immunotherapies in cutaneous pathologies: an overview. Drug Discov Today. 2021;26:248–255.
   PubMed Web of Science ®Google Scholar
• Singh S, Armstrong AW. Oral small molecules for psoriasis. Semin Cutan Med Surg. 2018;37:163–166.
   PubMed Web of Science ®Google Scholar
• Siegel SAR, Winthrop KL. In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis. Curr Rheumatol Rep. 2019;21:36.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–390.
   PubMed Web of Science ®Google Scholar
• Li X, Kong L, Li F, et al. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One. 2015;10:e0145221.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Zabotti A, Del Zotto S, et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2019;15:87–93.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Srivali N, Thongprayoon C. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Dermatolog Treat. 2016;27:316–321.
   PubMed Web of Science ®Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management. J Am Acad Dermatol. 2017;76:393–403.
   PubMed Web of Science ®Google Scholar
• Reid C, Cordingley L, Warren RB, et al. Progress to date in advancing stratified medicine in psoriasis. Am J Clin Dermatol. 2020;21:619–626.
   PubMed Web of Science ®Google Scholar
• Kaine J, Song X, Kim G, et al. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J Manag Care Spec Pharm. 2019;25:122–132.
   PubMed Web of Science ®Google Scholar
• Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative. Australas J Dermatol. 2019;60:91–98.
   PubMed Web of Science ®Google Scholar
• Wakkee M, de Vries E, van Den Haak P, et al. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol. 2011;65:1135–1144.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Shin DB, Ogdie A, et al. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138:1726–1735.
   PubMed Web of Science ®Google Scholar
• Kao LT, Lee CZ, Liu SP, et al. Psoriasis and the risk of pneumonia: a population-based study. PLoS One. 2014;9:e116077.
   PubMed Web of Science ®Google Scholar
• Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016;75:287–296.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–592.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol. 2016;50:377–389.
   PubMed Web of Science ®Google Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33:13–23.
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from the German psoriasis registry psobest. Arch Dermatol Res. 2015;307:875–883.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151:961–969.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Cohen AD, Cazzaniga S, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of psonet registries. J Am Acad Dermatol. 2017;76:299–308 e16.
   PubMed Web of Science ®Google Scholar
• Dobry AS, Quesenberry CP, Ray GT, et al. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017;77:838–844.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Kim SC, Lee MP, et al. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155:1142–1152.
   PubMed Web of Science ®Google Scholar
• Li X, Andersen KM, Chang HY, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79:285–291.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Bianchi C, Pescitelli L, et al. Risk of acute infections in psoriatic patients during biologic therapies is linked to gender. J Eur Acad Dermatol Venereol. 2019;33:e362–e4.
   PubMed Web of Science ®Google Scholar
• Lee MP, Wu KK, Lee EB, et al. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. Cutis. 2020;106:199–205.
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1676–1684.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian psocare registry. Br J Dermatol. 2015;172:1613–1620.
   PubMed Web of Science ®Google Scholar
• Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:341–342.
   PubMed Web of Science ®Google Scholar
• Di Girolamo C, Pappone N, Melillo E, et al. Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. Br J Rheumatol. 1998;37:1136–1137.
   PubMedGoogle Scholar
• Smith JD, Knox JM. Psoriasis, methotrexate and tuberculosis. Br J Dermatol. 1971;84:590–593.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461–2498.
   PubMed Web of Science ®Google Scholar
• Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445–1486.
   PubMed Web of Science ®Google Scholar
• Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35:824–834.
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503–509.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. Am J Clin Dermatol. 2019;20:829–845.
   PubMed Web of Science ®Google Scholar
• Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. Herpes zoster, hepatitis c, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis. Clin Epidemiol. 2020;12:153–161.
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77:88–97 e5.
   PubMed Web of Science ®Google Scholar
• Alpalhao M, Borges-Costa J, Filipe P. Psoriasis in HIV infection: an update. Int J STD AIDS. 2019;30:596–604.
   PubMed Web of Science ®Google Scholar
• Couderc S, Lapeyre-Mestre M, Bourrel R, et al. Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. Fundam Clin Pharmacol. 2018;32:436–449.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with self-reported psoriatic arthritis from the psoriasis longitudinal assessment and registry (PSOLAR) treated with biologics. BMC Rheumatol. 2019;3:52.
   PubMedGoogle Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21:271–277.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of serious Infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138:534–541.
   PubMed Web of Science ®Google Scholar
• Dauden E, Carretero G, Rivera R, et al. Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish registry of adverse events for biological therapy in dermatological diseases (BIOBADADERM) registry. J Am Acad Dermatol. 2020;83:139–150.
   PubMed Web of Science ®Google Scholar
• Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.
   PubMed Web of Science ®Google Scholar
• Cowan LT, Lutsey PL, Pankow JS, et al. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc. 2018;7:e009683.
   PubMed Web of Science ®Google Scholar
• Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30:424–428.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Madrange M, Viguier M, et al. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol. 2019;181:1304–1306.
   PubMed Web of Science ®Google Scholar
• Szwed P, Gasecka A, and Zawadka M, et al. Infections as novel risk factors of atherosclerotic cardiovascular diseases: pathophysiological links and therapeutic implications. J Clin Med. 2021;10:2539.
   Web of Science ®Google Scholar
• Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.
   PubMed Web of Science ®Google Scholar
• Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340–2346.
   PubMed Web of Science ®Google Scholar
• Buddeke J, Bots ML, van Dis I, et al. Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data. Br J Gen Pract. 2019;69:e398–e406.
   PubMed Web of Science ®Google Scholar
• Grodner C, Sbidian E, Weill A, et al. Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database. J Eur Acad Dermatol Venereol. 2021;35:411–416.
   PubMed Web of Science ®Google Scholar
• Iskandar IY, Ashcroft DM, Warren RB, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173:510–518.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171:137–147.
   PubMed Web of Science ®Google Scholar
• Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35:1209–1215.
   PubMed Web of Science ®Google Scholar
• Struyf T, Nuyts S, Tournoy J, et al. Burden of infections on older patients presenting to general practice: a registry-based study. Fam Pract. 2021;38:166–172.
   PubMed Web of Science ®Google Scholar
• Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5:212–227.
   PubMedGoogle Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84–91.
   PubMed Web of Science ®Google Scholar
• Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044.
   PubMed Web of Science ®Google Scholar
• Ferlita S, Yegiazaryan A, and Noori N, et al. Type 2 diabetes mellitus and altered immune system leading to susceptibility to pathogens, especially mycobacterium tuberculosis. J Clin Med. 2019;8:2219.
   Web of Science ®Google Scholar
• Harding JL, Benoit SR, Gregg EW, et al. Trends in rates of Infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000-2015. Diabetes Care. 2020;43:106–116.
   PubMed Web of Science ®Google Scholar
• Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232:633–639.
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37:333–340.
   PubMed Web of Science ®Google Scholar
• Chu Y, Yang J, Shi J, et al. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. Eur J Med Res. 2020;25:64.
   PubMed Web of Science ®Google Scholar
• Llamas-Velasco M, Ovejero-Merino E, and Salgado-Boquete L. Obesity - a risk factor for psoriasis and COVID-19. Actas Dermosifiliogr. 2021;112:489-494 .
   Web of Science ®Google Scholar
• O’Rourke RW, and Lumeng CN. Pathways to severe COVID-19 for people with obesity. Obesity (Silver Spring). 2021;29:645–653 .
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147–151.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23:561–565.
   PubMed Web of Science ®Google Scholar
• Li WQ, Han JL, Chan AT, et al. Psoriasis, psoriatic arthritis and increased risk of incident crohn’s disease in US women. Ann Rheum Dis. 2013;72:1200–1205.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Bateman BT, Huybrechts KF, et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017;356:j895.
   PubMed Web of Science ®Google Scholar
• Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15:969–979.
   PubMed Web of Science ®Google Scholar
• Storme O, Tiran Saucedo J, Garcia-Mora A, et al. Risk factors and predisposing conditions for urinary tract infection. Ther Adv Urol. 2019;11:1756287218814382.
   Web of Science ®Google Scholar
• Sahuquillo-Torralba A, Carretero G, Rivera R, et al. The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study. J Am Acad Dermatol. 2020;82:738–741.
   PubMed Web of Science ®Google Scholar
• Srinivas C, Odsbu I, Linder M. Risk of common infections among individuals with psoriasis in Sweden: a nationwide cohort study comparing secukinumab to ustekinumab. Pharmacoepidemiol Drug Saf. 2020;29:1562–1569.
   PubMed Web of Science ®Google Scholar
• Smith SD, Conrad C, Ramharter M, et al. Integrated safety analysis: frequency of urinary tract infections in patients with psoriasis treated with ixekizumab. J Am Acad Dermatol. 2020;83:261–263.
   PubMed Web of Science ®Google Scholar
• Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related Infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:882–913.
   PubMed Web of Science ®Google Scholar
• Rolston KV. Infections in cancer patients with solid tumors: a review. Infect Dis Ther. 2017;6:69–83.
   PubMed Web of Science ®Google Scholar
• Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009;129:2604–2612.
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152:282–290.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194–2201.
   PubMed Web of Science ®Google Scholar
• Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778–783.
   PubMed Web of Science ®Google Scholar
• Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27:36–46.
   PubMed Web of Science ®Google Scholar
• Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of Adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119–130.
   PubMed Web of Science ®Google Scholar
• Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–1904.
   PubMed Web of Science ®Google Scholar
• Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. Bmj. 2013;346:f1939.
   PubMed Web of Science ®Google Scholar
• Fishman JA. Infection in organ transplantation. Am J Transplant. 2017;17:856–879.
   PubMed Web of Science ®Google Scholar
• Garrouste C, Anglicheau D, Kamar N, et al. Anti-TNFalpha therapy for chronic inflammatory disease in kidney transplant recipients: clinical outcomes. Medicine (Baltimore). 2016;95:e5108.
   PubMed Web of Science ®Google Scholar
• Lora V, Graceffa D, De Felice C, et al. Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection. Dermatol Ther. 2019;32:e12909.
   PubMed Web of Science ®Google Scholar
• Schon MP, Berking C, Biedermann T, et al. COVID-19 and immunological regulations - from basic and translational aspects to clinical implications. J Dtsch Dermatol Ges. 2020;18:795–807.
   Web of Science ®Google Scholar
• Sadeghi A, Tahmasebi S, Mahmood A, et al. Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J Cell Physiol. 2021;236:2829–2839.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645–653.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147:60–71.
   PubMed Web of Science ®Google Scholar
• de Lem W, Joustra MM, Olydam JI, et al. COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data. J Eur Acad Dermatol Venereol. 2021;35:e173–e6.
   PubMed Web of Science ®Google Scholar
• Ö K, Metin A. Dermatological diseases presented before COVID-19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther. 2020;33:e13509.
   PubMed Web of Science ®Google Scholar
• Amerio P, Prignano F, Giuliani F, et al. COVID-19 and psoriasis: should we fear for patients treated with biologics? Dermatol Ther. 2020;33:e13434.
   PubMed Web of Science ®Google Scholar
• Elmas ÖF, Demirbaş A, and Ö K, et al. Psoriasis and COVID-19: a narrative review with treatment considerations. Dermatol Ther. 2020;33:e13858.
   PubMed Web of Science ®Google Scholar
• Ricardo JW, and Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020;33:e13687.
   PubMed Web of Science ®Google Scholar
• De Simone C, Amerio P, and Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13 :1673-1682.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, et al. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. J Eur Acad Dermatol Venereol. 2020;34:e770–e2.
   PubMed Web of Science ®Google Scholar
• Baniandres-Rodriguez O, Vilar-Alejo J, Rivera R, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis. J Am Acad Dermatol. 2021;84:513–517.
   PubMed Web of Science ®Google Scholar
• Melis D, Mugheddu C, Sanna S, et al. Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult psoriasis during COVID-19 pandemic. Dermatol Ther. 2020;33:e13722.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Pizzatti L, Sanna S, et al. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management. J Eur Acad Dermatol Venereol. 2020;34:e376–e8.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology. Available at: https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics. Accessed 2 Dec, 2020.
   Google Scholar
• Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation Covid-19 task force guidance for management of psoriatic disease during the pandemic: version 1. J Am Acad Dermatol. 2020;83:1704–1716.
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Ricceri F, Prignano F. Tuberculosis reactivation risk in dermatology. J Rheumatol Suppl. 2014;91:65–70.
   PubMedGoogle Scholar